Celldex Therapeutics, Inc. (CLDX) Operating Margin
- Operating margin · 12 months: Value -206220.25%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -206220.25% | Operating income / revenue. Period ending 2026-06-30. $-325.83M ÷ $158.00K × 100 ≈ -206220.25% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -325.83M USD | Operating Income (Loss) |
| Revenue | 158.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 278.81M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-325.83M | $158.00K | (m) | $278.81M | (m) | -206220.25% |
| 2026-03-31 | $-309.06M | $865.00K | (m) | $265.46M | (m) | -35729.83% |
| 2025-12-31 | $-287.37M | $1.54M | $200.00K | $245.07M | (m) | -18599.81% |
| 2025-09-30 | $-256.24M | $2.60M | (m) | $216.68M | (m) | -9859.22% |
| 2025-06-30 | $-234.75M | $5.79M | (m) | $199.01M | (m) | -4054.40% |
| 2025-03-31 | $-217.21M | $7.56M | (m) | $184.50M | (m) | -2873.52% |
| 2024-12-31 | $-195.08M | $7.02M | $200.00K | $163.55M | (m) | -2778.89% |
| 2024-09-30 | $-186.68M | $9.98M | (m) | $147.04M | (m) | -1871.27% |
| 2024-06-30 | $-175.79M | $8.30M | (m) | $136.31M | (m) | -2117.20% |
| 2024-03-31 | $-162.68M | $6.07M | (m) | $122.87M | (m) | -2679.17% |
| 2023-12-31 | $-154.54M | $6.88M | $300.00K | $118.01M | (m) | -2245.27% |
| 2023-09-30 | $-134.80M | $4.37M | (m) | $110.48M | (m) | -3088.20% |
| 2023-06-30 | $-121.26M | $3.25M | (m) | $97.52M | (m) | -3726.40% |
| 2023-03-31 | $-124.45M | $3.15M | (m) | $92.00M | (m) | -3950.73% |
| 2022-12-31 | $-115.23M | $2.36M | $100.00K | $82.26M | (m) | -4889.01% |
| 2022-09-30 | $-107.69M | $1.08M | (m) | $74.04M | (m) | -9989.70% |
| 2022-06-30 | $-100.82M | $823.00K | (m) | $66.02M | (m) | -12250.06% |
| 2022-03-31 | $-77.86M | $4.14M | (m) | $57.65M | (m) | -1880.70% |
| 2021-12-31 | $-71.24M | $4.65M | $100.00K | $53.31M | (m) | -1531.78% |
| 2021-09-30 | $-75.68M | $8.10M | (m) | $49.06M | (m) | -934.14% |
| 2021-06-30 | $-69.20M | $8.62M | (m) | $46.21M | (m) | -802.98% |
| 2021-03-31 | $-67.13M | $5.38M | (m) | $43.56M | (m) | -1248.86% |
| 2020-12-31 | $-63.35M | $7.42M | $200.00K | $42.53M | (m) | -854.06% |
| 2020-09-30 | $-51.56M | $4.52M | (m) | $42.45M | (m) | -1140.75% |
| 2020-06-30 | $-49.06M | $4.40M | (m) | $42.84M | (m) | -1115.60% |
| 2020-03-31 | $-49.96M | $4.88M | (m) | $43.22M | (m) | -1024.55% |
| 2019-12-31 | $-55.03M | $3.57M | $100.00K | $42.67M | (m) | -1540.19% |
| 2019-09-30 | $-54.16M | $4.45M | (m) | $43.54M | (m) | -1217.19% |
| 2019-06-30 | $-50.09M | $4.84M | (m) | $44.36M | (m) | -1033.98% |
| 2019-03-31 | $-54.70M | $6.89M | (m) | $55.73M | (m) | -793.33% |
| 2018-12-31 | $-156.44M | $9.54M | $700.00K | $66.45M | (m) | -1640.13% |
| 2018-09-30 | $-169.84M | $11.23M | (m) | $78.71M | (m) | -1512.37% |
| 2018-06-30 | $-194.03M | $14.21M | (m) | $88.70M | (m) | -1365.10% |
| 2018-03-31 | $-206.09M | (m) | (m) | $92.25M | (m) | (m) |
| 2017-12-31 | $-121.53M | $12.74M | (m) | $96.17M | (m) | -953.68% |
| 2017-09-30 | $-130.85M | $11.16M | (m) | $97.27M | (m) | -1172.52% |
| 2017-06-30 | $-128.89M | $9.46M | (m) | $100.36M | (m) | -1362.86% |
| 2017-03-31 | $-132.32M | $7.02M | (m) | $101.07M | (m) | -1885.76% |
| 2016-12-31 | $-132.92M | $6.79M | (m) | $102.73M | (m) | -1958.68% |
| 2016-09-30 | $-131.50M | $6.70M | (m) | $102.07M | (m) | -1961.55% |
| 2016-06-30 | $-133.88M | $5.51M | (m) | $101.71M | (m) | -2430.65% |
| 2016-03-31 | $-134.26M | $6.30M | (m) | $102.49M | (m) | -2132.19% |
| 2015-12-31 | $-129.54M | $5.48M | (m) | $100.17M | (m) | -2363.89% |
| 2015-09-30 | $-128.15M | $5.17M | (m) | $103.30M | (m) | -2480.72% |
| 2015-06-30 | $-126.12M | $5.24M | (m) | $104.83M | (m) | -2406.03% |
| 2015-03-31 | $-121.92M | $3.66M | (m) | $102.44M | (m) | -3334.85% |
| 2014-12-31 | $-122.43M | $3.59M | (m) | $104.38M | (m) | -3414.11% |
| 2014-09-30 | $-112.49M | $2.73M | (m) | $95.16M | (m) | -4122.13% |
| 2014-06-30 | $-105.42M | $2.61M | (m) | $89.39M | (m) | -4042.18% |
| 2014-03-31 | $-95.53M | $2.11M | (m) | $80.38M | (m) | -4521.06% |
| 2013-12-31 | $-81.44M | $4.11M | (m) | $67.40M | (m) | -1981.08% |
| 2013-09-30 | $-75.88M | $7.14M | (m) | $63.34M | (m) | -1063.01% |
| 2013-06-30 | $-67.36M | $9.27M | (m) | $54.70M | (m) | -726.57% |
| 2013-03-31 | $-62.19M | $11.18M | (m) | $50.72M | (m) | -556.11% |
| 2012-12-31 | $-58.08M | $11.20M | (m) | $47.40M | (m) | -518.45% |
| 2012-09-30 | $-53.91M | $9.99M | (m) | $43.47M | (m) | -539.69% |
| 2012-06-30 | $-50.64M | $9.24M | (m) | $40.30M | (m) | -548.08% |
| 2012-03-31 | $-47.03M | $9.18M | (m) | $36.35M | (m) | -512.19% |
| 2011-12-31 | $-43.40M | $9.27M | (m) | $32.44M | (m) | -468.42% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-6.46M | $46.79M | (m) | $27.65M | (m) | -13.79% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-36.85M | $15.18M | (m) | $26.17M | (m) | -242.75% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |